logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
Showing 1 - 20 of 33 Items
Showing 1 - 20 of 33 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Review
Journal Article
|
Review
Journal Article
|
Commentary
Journal Article
|
Editorial
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Video

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract
Journal Article
|
Letter

Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Review
Journal Article
|
Letter

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes

Campbell JR, Chan ED, Anderson LF, Bonnet M, Brode SK, 
Journal Article
|
Commentary

Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations

Varaine FFV, Guglielmetti L, Mitnick CD
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Commentary

WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?

Guglielmetti L, Huerga H, Khan UT, Varaine T
2020-03-01 • European Respiratory Journal
2020-03-01 • European Respiratory Journal
Journal Article
|
Letter
Journal Article
|
Commentary
Journal Article
|
Commentary

Clinical best practices for caring for people with expanded resistance to newer TB drugs

Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi S,  et al.
2025-06-13 • IJTLD OPEN
2025-06-13 • IJTLD OPEN

BACKGROUND

Strains of Mycobacterium tuberculosis

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J,  et al.
2025-06-06 • Lancet Infectious Diseases
2025-06-06 • Lancet Infectious Diseases

Equitable, personalised medicine for tuberculosis: Treating patients, not diseases

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C,  et al.
2025-03-21 • Lancet Respiratory Medicine
2025-03-21 • Lancet Respiratory Medicine

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Rupasinghe P, 
Ashraf A, 
Barreda N, 
Parveen S, 
Zubair M, 
et al.
2024-05-02 • Antimicrobial Agents and Chemotherapy
2024-05-02 • Antimicrobial Agents and Chemotherapy

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Recent advances in the treatment of tuberculosis

Motta I, Boeree M, Chesov D, Dheda K, Günther G,  et al.
2023-07-21 • Clinical Microbiology and Infection
2023-07-21 • Clinical Microbiology and Infection
BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...
et al.
2023-04-01 • International Journal of Tuberculosis and Lung Disease
2023-04-01 • International Journal of Tuberculosis and Lung Disease

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine

Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring

Hewison CCH, Guglielmetti L
2021-02-12 • Lancet Infectious Diseases
2021-02-12 • Lancet Infectious Diseases
We are not alone in welcoming the study by Kelly E Dooley and colleagues 1 that sheds light on the QT prolonging effects of the combination of bedaquiline and delamanid, two key drugs fo...

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S,  et al.
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...